Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye

<div>Functional outcomes over time for eyes with mCNV with different axial lengths. All groups showed BCVA improvement from baseline to the final 12-month follow-up; however, the group with axial length &lt;28 mm showed the greatest letter gain.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye 